Mobile Medical Nasopharyngeal Carcinoma mRNA CTCs Specified Screening

CTCs Early Screening Nasopharyngeal Tumor
-Detecting tumor of 0.2cm or more
-Non-invasive and inflicting minimal harm
-Accuracy, sensitivity and specificity up to 93-97%

What is mRNA circulating tumor cells screening?
Unlike DNA screening, mRNA screening detects the production of mRNA (an essential component before protein synthesis) instead of analyzing the gene sequences. When the cells are in active mode, the genes are highly activated. In order to produce enough protein to work in the body, the production of mRNA will be increased. By detecting the production of disease-associated mRNA molecular markers, it helps to assess your health status, such as whether you are sick , the current stage of the disease, the treatment status,etc.

Why do you need to do mRNA circulating tumor cell screening?
With the brand new mRNA dynamic gene technology, we can detect the number of circulating tumor cells in the body, and rule out the presence of tumor cells in an extremely early stage. This advanced technology can detect tumors of 0.2cm or more with just only a small amount of blood sample. Its accuracy, sensitivity and specificity can reach up to 93-97%. It is an earlier detection approach compare with other imaging test such as CT, MRI and PET Scan. (Those imaging tests can only detect tumors with 0.5cm or above)!

Advantage:
- Nasopharyngeal Carcinoma tumor screening in an extremely early stage, with the tumor size as tiny as 0.2 cm or above
- Accuracy, sensitivity and specificity up to 93-97%
- Only a small amount of blood sample is needed, safer than other imaging test with no radiation involved
- If you need to track your status regularly, it is absolutely convenient with radiation-free procedure.